Rafael Gonzalez, MD
Advertisement
Articles by Rafael Gonzalez, MD
Advertisement
Latest Updated Articles
Cost-Effectiveness of Frontline PARP Inhibitor Maintenance in Advanced Ovarian CancerPublished: April 21st 2020 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5